Look at the insiders list. Craig Wheeler sold $10 million last year. Was that for all the good deals he made? This is a company with good science, only one CEO away from success!
Craig Wheeler "director", who manages to sell a ton of stock at best prices. He is the enemy of stock holders. Selling $10 million of MNTA (just last year!) while screwing-up every deal he ever made.
No news when Novartis reported earnings( glatopa ) looks like sales very small. The payment from Mylan will not show up till next qtr. And it seams mkt is discounting it already. With all the talk about high drug prices would of expected this as a generic co to hold a little better. Looking for some catalyst to move it higher but do not see any thing on the horizon till late 2017, 2018 if they can deliver.
Thx went and read their announcement. This may be due to other treatments and not from
Glatopa. They (TEVA) has converted 78 percent to 3 time formulation. Waiting t to hear MNTA cc to make any determination. Talked about strong 3 times patent protection till 2030. NVS gave no breakout numbers when they reported on Glatopa sales. But they did for some of their other products.
There is no buying level until they they they start showing some progress. Their performance is miserable and if they continue on that path they'll be gone in a couple of years.
No body seems to want to own this. The secondary at 19 is making everyone think they got *&*^% by the underwriters, All management does is sell their awards and every day comes closer to a new entrant in the copaxone copy market, that TEVA still keeping most for themselves. With upcoming investor conference spending more money they are not making.
No news about the $millions. Perhaps that is all a fake. This "company" is looking more and more like the personal "candy store" for a few insiders.
They were lucky to sell ~8M shares in May - June last year for $19 to get some cash, just before the lunch of Glatopa. Unfortunately with this pace of losing they will lose all those cash they risen in 5 quarters but will have more shares. If they get $45M by March 11 from Mylan , they possibly will delay the beading by one quarter and book one time profit.
Cant seem to break Teva's grasp on the Copaxone mkt. Enoxoparin dead in the water- their not even talking about any benefit coming from that asset on any level. While their analytics are sound they can't seam to generate any sustainable product line that will move them to profitability.
While momenta can produce biosimilars. The markets for them keep getting smaller due to new drug introductions by a number of competitors. Their novel drug business is at best suspect. This company has always been a show me- but they can not , kind of company.JMHO
Do not exaggerate. :) maybe in a couple of years after they lose another $200M w/o generation any new money flow. They still have ~$5 per share in cash. However, can they get another 20-40% haircut - absolutely.
Whatever your doing, stop it now and join ULTIMATE STOCK ALERTS (google them). I am serious, if you like to trade Nasdaq and nyse small cap momentum stocks this is a MUST DO.
Overreacted. No reason this stock went down 20% in two days. You will make money if you buy is today.
Sentiment: Strong Buy